Microbial and Biochemical Pharmacy

current position:

Home - Education - Master Supervisor - Microbial and Biochemical Pharmacy





NameJing Zhang

DepartmentNational Center for Screening Novel Microbial Drugs, Institute of Medicinal Biotechnology, Chinese Academy of Medical Sciences and Peking Union Medical College

Tel: (8610)63180623

Email: jingjingz@imb.pumc.edu.cn

Education & Research Experience

2018/08 – 2019/08 Visiting Scholar under the State Scholarship Fund, Henry Ford Hospital Immunology program

2016/09 – Now Associate Professor, Institute of Medicinal Biotechnology, Chinese Academy of Medical Sciences

2009/09 – 2016/09 Assistant Professor, Institute of Medicinal Biotechnology, Chinese Academy of Medical Sciences

2006/09 – 2009/07 Ph.D. in Microbial and Biochemical Pharmacy, Peking Union Medical College

2003/09 – 2006/07 M.S. in Molecular Biology , Capital Normal University

1999/09 – 2003/07 B.S. in Biology of Science, Hebei Normal University

Research Field

Discovery of antiviral or antitumor drugs and research on their mechanism

Research Interests

Dr. Zhang’s research has been focused on establishing high throughput screening (HTS) models for identifying lead compounds which have anti-viral or anti-tumor activities. The main content include: 1) establishment of HTS models targeting proteins of virus or tumor in vitro; 2) identification of lead compounds which have anti-viral or anti-tumor activities via HTS; 3) research on the molecular mechanism of the lead compounds and structural modification.

Dr. Zhang has gotten research support such as National Natural Science Foundation of China, CAMS Fundamental Research Funds, and so on.

Selected Publications

1. Li Y#, Zhu X#, Zhang J, Lin Y, You X, Chen M, Wang Y, Zhu N*, Si S*. Identification of a Compound That Inhibits the Growth of Gram-Negative Bacteria by Blocking BamA-BamD Interaction. Front Microbiol. 2020Jun 19;11:1252.

2. Yunyu Chen1#, Jing Zhang1#, Dongsheng Li1, Jiandong Jiang1, Yanchang Wang2, Shuyi Si1.Identification of a Novel Polo-like Kinase 1 Inhibitor that Specifically Blocks Polo-Box Domain-Mediated Protein-Protein Interactions. Oncotarget. 2017,8(1):1234-1246.  

3. Han X#, Zhang J#, Guo L, Cao R, Li Y, Li N, Ma Q, Wu J*, Wang Y*, Si S*. A series of beta-carboline derivatives inhibit the kinase activity of PLKs. PLoS one,7(10):e46546. Epub 2012 Oct 3.

4.Yuan Lina,1, Yan Lia,1, Yuanjun Zhua,c, Jing Zhanga, Yongzhen Lia, Xiao Liua,Chunling Xiaoa, Bin Honga, Jiandong Jianga,2, Yanchang Wangb,2, Shuyi Sia,2. Identification of anti-tuberculosis agents that target ribosome subunit interaction using yeast two-hybrid system. Proc Natl Acad Sci U S A, 2012 Oct 23;109(43):17412-17417.

5. Jing Zhang#, Yan Li#, Liang Guo, Rihui Cao, Pei Zhao, Wei Jiang, Qin Ma, Hong Yi, Zhuorong Li, Jiandong Jiang, Jialin Wu*, Yanchang Wang*, Shuyi Si*. DH166, a beta-carboline derivative, inhibits the kinase activity of PLK1. Cancer Biol Ther,2009,8(24): 2374-2383.

Academic Appointments

Youth committee of Division of anti-inflammatory and immunological pharmacologyChinese Pharmacological Society